Featured Research

from universities, journals, and other organizations

The factor that could determine future breast cancer treatment

Date:
December 27, 2012
Source:
Garvan Institute of Medical Research
Summary:
Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors. Transcription factors are molecules that switch genes on or off. In this case, the transcription factor known as 'ELF5' inhibits sensitivity to oestrogen very early in the life of a breast cancer cell.

Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to estrogen and does not respond to anti-estrogen therapies such as Tamoxifen and aromatase inhibitors.

Transcription factors are molecules that switch genes on or off. In this case, the transcription factor known as 'ELF5' inhibits sensitivity to estrogen very early in the life of a breast cancer cell.

In 2008, Associate Professor Chris Ormandy from Sydney's Garvan Institute of Medical Research showed that ELF5 was responsible for the development of the estrogen-receptor-negative cells in the breast during pregnancy that produce milk.

In the current study Ormandy, in collaboration with Drs Maria Kalyuga and David Gallego-Ortega, has shown that the same molecular decision occurs in breast cancer and that ELF5 has the ability to change an existing tumour to an estrogen-insensitive type.

The team has also described the genetic mechanisms by which ELF5 opposes the action of estrogen, and has shown that it is possible to alter the subtype of breast cancer by manipulating ELF5 levels. The findings are published in the online journal PLoS Biology.

"This work tells us that cancers which become refractory to anti-estrogen treatment often do so by elevating their levels of ELF5 and becoming functionally estrogen receptor negative," said Ormandy.

"This raises the therapeutic option of manipulating ELF5 levels to treat breast cancer."

"As ELF5 is intracellular, this could possibly be done with small molecule therapies that target protein-to-protein interactions, or with small inhibitory RNAs."

"There is also the possibility of testing ELF5 levels in tumours to predict response to treatment and therefore guide treatment decisions."

"Our key discovery here is that by simply manipulating one transcription factor we can change the subtype of breast cancer."


Story Source:

The above story is based on materials provided by Garvan Institute of Medical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maria Kalyuga, David Gallego-Ortega, Heather J. Lee, Daniel L. Roden, Mark J. Cowley, C. Elizabeth Caldon, Andrew Stone, Stephanie L. Allerdice, Fatima Valdes-Mora, Rosalind Launchbury, Aaron L. Statham, Nicola Armstrong, M. Chehani Alles, Adelaide Young, Andrea Egger, Wendy Au, Catherine L. Piggin, Cara J. Evans, Anita Ledger, Tilman Brummer, Samantha R. Oakes, Warren Kaplan, Julia M. W. Gee, Robert I. Nicholson, Robert L. Sutherland, Alexander Swarbrick, Matthew J. Naylor, Susan J. Clark, Jason S. Carroll, Christopher J. Ormandy. ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS Biology, 2012; 10 (12): e1001461 DOI: 10.1371/journal.pbio.1001461

Cite This Page:

Garvan Institute of Medical Research. "The factor that could determine future breast cancer treatment." ScienceDaily. ScienceDaily, 27 December 2012. <www.sciencedaily.com/releases/2012/12/121227173330.htm>.
Garvan Institute of Medical Research. (2012, December 27). The factor that could determine future breast cancer treatment. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2012/12/121227173330.htm
Garvan Institute of Medical Research. "The factor that could determine future breast cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2012/12/121227173330.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins